PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

交易中 07-06 11:25:16 EDT

9.90

-0.06

-0.65%

最高9.96	最低9.70	成交量34.73万
今开9.86	昨收9.97	日振幅2.61%
总市值7.64亿	流通市值6.95亿	总股本7,712万
成交额341.99万	换手率0.49%	流通股本7,018万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":9.9,"timestamp":1783351515699,"preClose":9.965,"halted":0,"volume":347333,"delay":0,"changeRate":-0.006522829904666282,"floatShares":70183956,"shares":77122565,"eps":2.117667,"marketStatus":"交易中","change":-0.065,"latestTime":"07-06 11:25:16 EDT","open":9.86,"high":9.96,"low":9.7,"amount":3419911.921265,"amplitude":0.026091,"askPrice":9.91,"askSize":300,"bidPrice":9.9,"bidSize":110,"shortable":3,"etf":0,"ttmEps":2.117667,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783368000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":9.965,"preHourTrading":{"tag":"盘前","latestPrice":9.95,"preClose":9.965,"latestTime":"05:45 EDT","volume":38,"amount":381.110018,"timestamp":1783331144859,"change":-0.015,"changeRate":-0.001505,"amplitude":0.010035},"postHourTrading":{"tag":"盘后","latestPrice":9.98,"preClose":9.98,"latestTime":"19:22 EDT","volume":127082,"amount":1268264.45,"timestamp":1783034579246,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.555839,"impliedVol":0.8476,"impliedVolPercentile":0.6892},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2648220025","title":"和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648220025?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:06","pubTimestamp":1782950774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4568","IE00BPRC5H50.USD","LU0432979614.USD","LU2456880835.USD","LU1267930573.SGD","LU2236285917.USD","LU0109394709.USD","LU0708994859.HKD","LU0128525929.USD","LU2237443895.HKD","LU2488822045.USD","BK4007","LU2476274720.SGD","LU2417539215.USD","LU2089984988.USD","BK4023","LU0889565916.HKD","LU2237443465.HKD","LU2476274308.USD","LU2237443622.USD","LU2462157665.USD","02256","LU2778985437.USD","LU0058720904.USD","IE00B3T34201.USD","BK4585","LU1829250122.USD","LU1169589451.USD","LU2237443549.SGD","IE00B5MMRT66.SGD","PD","LU2237443382.USD","LU0320765992.SGD","LU0289739699.SGD","LU0029864427.USD","BK4588","IE00B543WZ88.USD","AZNH","LU2237443978.SGD","LU2468319806.SGD","AZN","LU1169590202.USD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642293703","title":"先声药业(02096)：SIM0689(PD-1/VEGF双特异性抗体)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642293703","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642293703?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:02","pubTimestamp":1781269339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，集团自主研发的靶向PD-1/ VEGF的双特异性抗体SIM0689已获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展晚期实体瘤的临床试验。SIM0689是一种同时靶向程序性死亡受体1(PD-1)和血管内皮生长因子(VEGF)特殊表位的双特异性抗体，通过解除肿瘤细胞免疫抑制和抗血管生成，发挥强效的抗肿瘤活性。在多种人源化小鼠药效模型中，SIM0689在低剂量即展现出优异的抗肿瘤疗效，整体药效显著优于同类型分子，提示其在多种实体瘤中有广泛的应用前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","02096","PD","BK1191","BK4023","BK1583","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642407722","title":"西南证券：PD~(L)1经治后耐药困局不容忽视 2026年催化密集","url":"https://stock-news.laohu8.com/highlight/detail?id=2642407722","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642407722?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:52","pubTimestamp":1781164329,"startTime":"0","endTime":"0","summary":"目前康方生物AK104联合普络西单抗(VEGFR2单抗)，取得了目前IO经治肺癌已披露研究数据中最长的OS，mOS=16.7mo。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260611/20260611152451_49256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260611/20260611152451_49256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0276","BK4107","LU2487616109.SGD","L","BK4585","BK0028","BK0188","BK0183","BK0012","600369","BK4588","LU1169589451.USD","BK4023","PD","LU0053666078.USD","LU0210528500.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640437984","title":"港股异动 | 康方生物(09926)高开逾9% 依沃西联合化疗战胜PD-1联合化疗OS结果发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2640437984","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640437984?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:24","pubTimestamp":1780277063,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物今日大幅高开，截至发稿，涨9.23%，报129港元，成交额3.62亿港元。消息面上，康方生物PD-1/VEGF双抗依沃西单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的III期HARMONi-6研究于ASCO大会全体会议公布最新结果。与替雷利珠单抗联合化疗相比，依沃西组患者死亡风险下降34%，OS达到统计学显著性，两年生存率64.7% vs 48.6%。HARMONi-6共入组532例患者，中央型鳞癌占比约63%，PD-L1 TPS＜1%患者占39%，多部位转移、肝转移及脑转移患者占比约33.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU0348783233.USD","LU0417516738.SGD","LU1169590202.USD","LU0348827113.USD","LU0348735423.USD","LU2476274308.USD","IE00B543WZ88.USD","LU2778985437.USD","BK4588","BK4585","IE00B5MMRT66.SGD","BK1161","BK4023","LU0540923850.HKD","LU2476274720.SGD","LU1794554557.SGD","LU1720050803.USD","LU0348766576.USD","VXUS","LU2399975544.HKD","09926","BK1574","LU0417516571.SGD","LU0417516902.SGD","LU1169589451.USD","PD","LU0634319403.HKD","LU0348767384.USD","LU0348784397.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639136988","title":"中国创新药迎高光！康方生物核心产品战胜PD-1联合化疗总生存期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2639136988","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639136988?lang=zh_cn&edition=full","pubTime":"2026-05-31 21:16","pubTimestamp":1780233368,"startTime":"0","endTime":"0","summary":"5月31日，《每日经济新闻》记者注意到，在2026年美国临床肿瘤学会（ASCO）年会上，康方生物（HK09926，股价118.10港元，市值1088亿港元）PD-1/VEGF双抗依沃西联合化疗对比替雷利珠单抗联合化疗，一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）III期HARMONi-6/AK112-306研究的OS（总生存期）显著阳性结果揭晓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605313755214061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605313755214061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348766576.USD","LU0348784397.USD","LU0348783233.USD","LU2476274308.USD","LU0417516902.SGD","LU1169590202.USD","LU1794554557.SGD","LU0348827113.USD","LU1961090484.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU1169589451.USD","LU2778985437.USD","LU0634319403.HKD","06978","LU2488822045.USD","BK1161","PD","159992","LU0348735423.USD","BK1574","LU0540923850.HKD","LU2399975544.HKD","LU0417516571.SGD","09926","LU0417516738.SGD","LU0348825331.USD","IE00B543WZ88.USD","LU0348767384.USD","LU1720050803.USD","LU0561508036.HKD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022270","title":"维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)治疗晚期肺外神经内分泌癌的III期临床研究获得CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636022270?lang=zh_cn&edition=full","pubTime":"2026-05-19 07:18","pubTimestamp":1779146304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。奥帕替苏米单抗已在肺外神经内分泌癌、非小细胞肺癌、小细胞肺癌及胆道癌四个适应症的注册性或II 期临床试验中展示出全球首创或同类最优潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082519.USD","BK1161","PD","CDE","09887","HK0000252160.HKD","HK0000500386.USD","LU1169589451.USD","LU1223083913.SGD","BK4134","BK4023","HK0000252152.HKD","LU1223082196.USD","BK4017","LU1169590202.USD","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630946589","title":"Incyte受益于PD-1抑制剂强劲需求，一季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2630946589","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630946589?lang=zh_cn&edition=full","pubTime":"2026-04-28 23:30","pubTimestamp":1777390200,"startTime":"0","endTime":"0","summary":"Incyte公布的2026年第一季度财报显示，得益于核心药物及癌症治疗组合的强劲需求，公司业绩超出了华尔街分析师的普遍预期。　　财报数据显示，Incyte本季度总收入实现了同比增长，主要驱动力来自其重磅药物以及与日本武田制药合作的资产。Incyte的核心产品销售增长显著，同时其他商业资产的专营权使用费收入也持续向好。　　基于第一季度的超预期表现，Incyte重申了其2026年全年的业绩指引，预计市场对其创新药物的需求将保持稳定。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-28/doc-inhwapms8394113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1169590202.USD","PD","BK4023","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629089166","title":"维立志博-B(09887)：维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)于一线胃或胃食管结合部腺癌II期试验的首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2629089166","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629089166?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:46","pubTimestamp":1776761213,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于治疗一线局部晚期或转移性胃或胃食管结合部腺癌的II期临床研究首例患者已成功入组。本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线局部晚期或转移性胃或胃食管结合部腺癌患者的有效性和安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03160","BK4023","HK0000252152.HKD","LU1169590202.USD","HK0000252160.HKD","HK0000500386.USD","TM","BK4585","09887","BK1161","LU1169589451.USD","BK4099","BK4588","BK4555","PD","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624933592","title":"三安光电(600703.SH)：用于车载的VCSEL、PD产品已实现小批量出货","url":"https://stock-news.laohu8.com/highlight/detail?id=2624933592","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624933592?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:27","pubTimestamp":1775039223,"startTime":"0","endTime":"0","summary":"格隆汇4月1日丨三安光电(600703.SH)在投资者互动平台表示，公司用于车载的VCSEL、PD产品已实现小批量出货，与头部新能源车企客户持续对接，以提升份额。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260401/32118972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","600703","BK0028","BK0064","BK0187","BK0070","BK0214","BK0012","BK4023","BK0196","LU1169589451.USD","LU1169590202.USD","BK0175","BK0188","PD","BK0141","BK0108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622858900","title":"基石药业-B(02616)公布PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展及I/II期关键临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2622858900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622858900?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:09","pubTimestamp":1774516159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展。在肺癌中展现强劲疗效：CS2009单药针对肺癌的I/II期初步疗效资料积极。截至2026年3月中旬，I期研究已共入组113例晚期实体瘤患者，中位元随访期约为6个月;II期研究已共入组85例患者。在TME中，PD-1和 CTLA-4的双重阻断作用通过与VEGFA的交联显著增强。同时，CS2009可优先结合PD-1和CTLA-4双阳性的肿瘤浸润T细胞，并最大程度上弱化对外周T细胞中CTLA-4调节通路的干扰。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","02616","BK1574","PD","BK4023","LU1169589451.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775502","title":"三安光电(600703.SH)：可提供用于800G光模块的CW光源、VCSEL、EML、PD、EMPD等激光器、探测器产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775502","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621775502?lang=zh_cn&edition=full","pubTime":"2026-03-23 15:57","pubTimestamp":1774252622,"startTime":"0","endTime":"0","summary":"格隆汇3月23日丨三安光电(600703.SH)在投资者互动平台表示，公司可提供用于800G光模块的CW光源、VCSEL、EML、PD、EMPD等激光器、探测器产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260323/32090105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0175","BK0141","LU0054578231.USD","BK0108","BK0214","BK4023","BK0187","600703","BK0028","PD","EMPD","EML","BK0183","BK0196","BK4091","BK0070","LU1169590202.USD","BK0188","BK0012","LU1169589451.USD","BK4187","BK4161","CW","BK0064"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782400","title":"复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)用于多种实体瘤治疗的1期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782400","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620782400?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:14","pubTimestamp":1774001646,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗的1期临床试验申请获国家药品监督管理局批准。部分肿瘤细胞的PD-1配体上调，通过这个通路信号传导可抑制激活的T细胞对肿瘤的免疫监视。2025年12月， HLX18于美国获许可开展用于多种实体瘤治疗的1期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306701.USD","HK0000306685.HKD","HK0000320264.USD","02696","LU1169589451.USD","PD","HK0000320223.HKD","LU1169590202.USD","BK4023","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617733596","title":"港股异动 | 基石药业-B(02616)涨超12% 公司自研PD-1/VEGF/CTLA-4三抗有望达成重磅BD","url":"https://stock-news.laohu8.com/highlight/detail?id=2617733596","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617733596?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:36","pubTimestamp":1772678196,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨超12%，截至发稿，涨12.71%，报6.65港元，成交额3695.43万港元。消息面上，基石药业-B此前发布公告称，公司核心资产CS2009用于晚期实体瘤的II期新药临床试验申请已经获得美国食品药品监督管理局批准。国元证券发布研报称，基石药业-B核心产品CS2009临床数据优异，安全性显著优于同类疗法，在IO经治NSCLC患者中ORR达17.6%，DCR达82.4%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4585","BK4023","02616","BK1161","LU1169589451.USD","VXUS","BK4588","PD","BK1574","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614035745","title":"患者死亡引 FDA 出手 PD-1/CTLA-4 双抗临床试验遇阻","url":"https://stock-news.laohu8.com/highlight/detail?id=2614035745","media":"生物制品圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614035745?lang=zh_cn&edition=full","pubTime":"2026-02-25 11:54","pubTimestamp":1771991682,"startTime":"0","endTime":"0","summary":"摘要：2026 年 2 月 24 日，FDA 下令叫停 MacroGenics 旗下核心药物 lorigerlimab 的二期临床试验入组工作，起因是试验中一名患者因严重副作用离世，另有四名患者出现严重不良反应。这家总部位于马里兰州的生物科技公司此前已自主暂停入组，此次 FDA 的指令让这款PD-1/CTLA-4 双抗药物的研发再添阴霾，而这并非该公司首次遭遇临床安全危机。隔天，FDA 的正式叫停指令落地，让这场自主暂停变成了官方强制的临床限制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225115824a4c58347&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225115824a4c58347&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PD","MGNX","BK4023","LU1169590202.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614773959","title":"君实生物与德琪医药达成战略合作，共同开展JS207（PD-1/VEGF双抗）与ATG-037（CD73口服小分子抑制剂）联合用药研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2614773959","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614773959?lang=zh_cn&edition=full","pubTime":"2026-02-25 08:30","pubTimestamp":1771979400,"startTime":"0","endTime":"0","summary":"上海2026年2月25日 /美通社/ -- 北京时间2026年2月25日，君实生物宣布与德琪医药达成战略合作，双方将共同探索君实生物自主研发的JS207与德琪医药的ATG-037在中国大陆肿瘤患者中的联合治疗协同潜力。本次合作的科学依据在于CD73抑制与PD-1/VEGF双靶向机制之间的互补性及潜在协同作用。综合上述因素，将CD73阻断与PD-1/VEGF靶向策略联合应用，有望增强并维持治疗效果。JS207可同时以高亲和力结合于PD-1与VEGFA，有效阻断PD-1与PD-L1和PD-L2的结合，并抑制VEGF与其受体的结合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4888412_ZH88412_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06996","BK1515","BK4023","BK1583","LU1169589451.USD","BK0239","PD","BK1574","688180","LU1169590202.USD","01877","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613179392","title":"Pagerduty, Inc.盘中异动 急速拉升5.19%报7.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613179392","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613179392?lang=zh_cn&edition=full","pubTime":"2026-02-20 23:04","pubTimestamp":1771599874,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日23时04分，Pagerduty, Inc.股票出现异动，股价快速拉升5.19%。截至发稿，该股报7.04美元/股，成交量29.822万股，换手率0.32%，振幅5.23%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为0.36%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220230435a70daac5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220230435a70daac5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169590202.USD","BK4023","LU1169589451.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612230016","title":"基石药业-B(02616)CS2009(PD-1/VEGF/CTLA-4三特异性抗体)II期临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2612230016","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612230016?lang=zh_cn&edition=full","pubTime":"2026-02-20 10:18","pubTimestamp":1771553881,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B宣布公司核心资产CS2009用于晚期实体瘤的II期临床试验IND申请已经获得FDA批准。CS2009用于晚期实体瘤的II期新药临床试验申请获美国食品药品监督管理局批准，标志着这一创新免疫疗法的全球开发取得重要进展。基石药业首席执行官、研发总裁及执行董事杨建新博士表示，非常高兴能够看到CS2009的全球多中心II期临床试验高效推进并获美国FDA批准开展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","02616","BK1161","LU1169590202.USD","PD","LU1169589451.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611171921","title":"基石药业-B(02616)：CS2009(PD-1/VEGF/CTLA-4三特异性抗体)II期临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611171921","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611171921?lang=zh_cn&edition=full","pubTime":"2026-02-16 08:08","pubTimestamp":1771200501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司核心资产CS2009用于晚期实体瘤的II期新药临床试验申请已经获得美国食品药品监督管理局批准。CS2009的I期临床研究初步数据已在2025年欧洲肿瘤内科学会年会上公布，安全性与耐受性良好，抗肿瘤活性数据积极。更多I期和II期临床研究数据预计将在今年召开的美国临床肿瘤学会和ESMO会议上公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","BK1161","LU1169589451.USD","02616","BK1574","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609752625","title":"复宏汉霖PD-1新药“出海”日本 最早将于2028年产生销售提成","url":"https://stock-news.laohu8.com/highlight/detail?id=2609752625","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609752625?lang=zh_cn&edition=full","pubTime":"2026-02-08 17:39","pubTimestamp":1770543568,"startTime":"0","endTime":"0","summary":"日前，上海复宏汉霖生物技术股份有限公司（以下简称“复宏汉霖”）与卫材株式会社（以下简称“卫材”）共同宣布，双方已就抗PD-1单抗汉斯状（斯鲁利单抗，以下简称“PD-1新药”）在日本达成一项独家商业化及共同独家开发与生产许可协议。汉斯状是复宏汉霖自主研发的一款PD-1新药。根据协议，卫材将获得汉斯状在日本的独家商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602083644840016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1169590202.USD","PD","BK1161","02696","HK0000320223.HKD","BK4023","HK0000306701.USD","HK0000320264.USD","LU1169589451.USD","HK0000165453.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609375221","title":"复宏汉霖携手卫材就抗PD-1单抗汉斯状达成日本市场合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2609375221","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609375221?lang=zh_cn&edition=full","pubTime":"2026-02-05 18:33","pubTimestamp":1770287601,"startTime":"0","endTime":"0","summary":"南方财经2月5日电，卫材与复宏汉霖今日共同宣布，双方已就抗PD-1单抗H药汉斯状?（斯鲁利单抗，欧洲商品名：Hetronifly?）在日本达成一项独家商业化及共同独家开发与生产许可协议。根据协议，卫材将向复宏汉霖支付7,500万美元的首付款，并在此基础上，支付最高不超过8,001万美元的监管里程碑付款，以及最高不超过2.333亿美元的销售里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642892718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306701.USD","BK4585","HK0000320264.USD","BK1161","LU1169589451.USD","BK4023","02696","BK4588","HK0000306685.HKD","HK0000320223.HKD","LU1169590202.USD","PD","HK0000165453.HKD","EWJ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":0.1659},{"period":"1month","weight":-0.0158},{"period":"3month","weight":0.5594},{"period":"6month","weight":-0.1945},{"period":"1year","weight":-0.3651},{"period":"ytd","weight":-0.2387}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律成立。该公司及其全资子公司提供了一个数字运营管理平台，为现代数字业务管理紧急和关键任务工作（“PagerDuty平台”）。PagerDuty平台从几乎任何支持软件的系统或设备收集数据和数字信号，并利用先进的人工智能和强大的机器学习实时关联、处理、预测和补救事件和机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.011871},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.075547},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.032883},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.032585},{"month":5,"riseRate":0.375,"avgChangeRate":0.055631},{"month":6,"riseRate":0.625,"avgChangeRate":0.015298},{"month":7,"riseRate":0.625,"avgChangeRate":0.019883},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.000522},{"month":9,"riseRate":0,"avgChangeRate":-0.114196},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.036422},{"month":11,"riseRate":0.571429,"avgChangeRate":0.021164},{"month":12,"riseRate":0.571429,"avgChangeRate":0.042574}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}